Author: kodiac

  • Agomelatine

    Plain-language summaryIntrigue 68 / 100

    Agomelatine is an antidepressant that combines melatonin receptor activation (sleep regulation) with 5-HT2C antagonism (mood). FDA declined approval; widely used in Europe under the brand Valdoxan. Not stocked by Kodiac. This monograph is provided for research and educational reference.

    Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

    Melatonergic MT1/MT2 receptor agonist with serotonin 5-HT2C receptor antagonism

    A naphthalenic melatonin analog developed at Servier as the first non-monoaminergic antidepressant, distinguished by dual melatonergic agonism and serotonin 5-HT2C antagonism that resynchronizes disrupted circadian rhythms while enhancing frontocortical dopaminergic and noradrenergic transmission.

    Abstract

    Agomelatine (S 20098) is a naphthalenic analog of melatonin and the first clinically approved antidepressant whose mechanism of action does not rely on direct modulation of monoamine reuptake or degradation. Developed by Servier Laboratories and granted European marketing authorization in 2009 under the trade names Valdoxan and Thymanax, agomelatine acts through high-affinity agonism at the melatonin MT1 and MT2 G-protein-coupled receptors (Ki approximately 0.1 nanomolar) combined with neutral antagonism at the serotonin 5-HT2C receptor (Ki approximately 630 nanomolar), a pharmacological profile that is unique among marketed antidepressants and that produces a synergistic downstream effect on circadian rhythm resynchronization, frontocortical dopamine and norepinephrine release, hippocampal neurogenesis, and brain-derived neurotrophic factor (BDNF) expression. The compound does not bind serotonin transporters, norepinephrine transporters, dopamine transporters, or any of the receptor families (muscarinic, histaminergic, adrenergic, GABAergic, glutamatergic, opioid) that produce the common adverse-event signatures of the selective serotonin reuptake inhibitor, serotonin-norepinephrine reuptake inhibitor, and tricyclic antidepressant classes, and consequently exhibits a tolerability profile characterized by the absence of sexual dysfunction, weight gain, discontinuation syndrome, and serotonin syndrome risk that distinguishes it from essentially all other antidepressant classes.

    Clinical efficacy in major depressive disorder has been established in multiple randomized, double-blind, placebo-controlled trials at the approved oral dose of 25 to 50 mg once daily at bedtime; pooled head-to-head analyses against fluoxetine, sertraline, venlafaxine, paroxetine, and escitalopram demonstrate broadly comparable antidepressant efficacy with superior tolerability and lower dropout rates. Relapse prevention has been demonstrated in a 24-week extension study with significantly lower cumulative relapse rate on agomelatine (24 percent) compared to placebo (50 percent). A separate clinical evidence base supports efficacy in generalized anxiety disorder, with randomized placebo-controlled trials demonstrating superiority on the Hamilton Anxiety Rating Scale and comparable efficacy to escitalopram with superior sleep restoration.

    Pharmacokinetics are dominated by extensive hepatic first-pass metabolism through cytochrome P450 1A2 (CYP1A2, accounting for approximately 90 percent of clearance) and CYP2C9/CYP2C19 (approximately 10 percent), producing an oral bioavailability of approximately 1 percent despite greater than 80 percent gastrointestinal absorption, a plasma elimination half-life of 1 to 2 hours, and high inter-individual variability driven principally by CYP1A2 activity. The major metabolites (3-hydroxy-agomelatine, 7-desmethyl-agomelatine, and 3-hydroxy-7-desmethyl-agomelatine) are pharmacologically inactive and are renally eliminated after conjugation. CYP1A2 induction by tobacco smoking reduces plasma concentrations three- to fourfold; strong CYP1A2 inhibitors (fluvoxamine, ciprofloxacin) increase exposure by up to 60-fold and are contraindicated in concurrent use.

    The principal safety concern specific to agomelatine is dose-dependent hepatotoxicity, manifesting as transaminase elevation greater than three times the upper limit of normal in approximately 1.3 percent of patients at 25 mg daily and 2.5 percent at 50 mg daily. Serious hepatic reactions including cytolytic hepatitis and rare hepatic failure have been reported in postmarketing surveillance. Regulatory authorities require liver function testing before treatment initiation, at approximately 3, 6, 12, and 24 weeks of treatment, and at dose increase. Withdrawal of agomelatine leads to rapid normalization of transaminases in essentially all reported cases. The compound is contraindicated in patients with hepatic impairment.

    This monograph reviews the chemistry, synthesis, and structural pharmacology of agomelatine; the dual-receptor mechanism in molecular and circadian detail; the comprehensive human pharmacokinetic record including CYP1A2 polymorphism and drug interactions; the clinical evidence base across major depressive disorder, generalized anxiety disorder, and sleep-related indications; the preclinical pharmacology including circadian, neurogenic, and anti-stress mechanisms; sourcing and quality verification for research applications; reconstitution and handling; stack-interaction considerations; the hepatotoxicity signal and broader adverse-event profile; and a comparative assessment of five alternative compounds (melatonin, ramelteon, tasimelteon, mirtazapine, vortioxetine) against agomelatine on five competency standards. The compound is not approved by the United States Food and Drug Administration. It is sold as a research-grade preparation outside its marketed antidepressant application; investigators should obtain analytical confirmation of identity and purity on every lot.

    Read the full monograph

    The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

    KDC-MN-072Open in new tab →

    Download PDF →

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

  • Amitriptyline

    Plain-language summaryIntrigue 65 / 100

    Amitriptyline (Elavil) is one of the founding tricyclic antidepressants, approved in 1961 and still in heavy clinical use, though almost never for depression anymore. At antidepressant doses (150 to 300 mg) the side-effect burden is rough: heavy sedation, dry mouth, constipation, weight gain, and blood pressure drops on standing. At low doses (10 to 75 mg) it has become a workhorse for chronic pain, particularly neuropathic pain, tension headache, and migraine prevention, where its effects on serotonin and norepinephrine signaling in spinal pain pathways do useful work. It also blocks sodium channels in the heart, which makes overdose genuinely dangerous and limits its use in anyone with cardiac conduction disease. Not stocked by Kodiac. This monograph is provided for research and educational reference.

    Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

    Tricyclic dibenzocycloheptadiene antidepressant with serotonin-norepinephrine reuptake inhibition and multi-target ion channel modulation

    A first-generation tricyclic antidepressant developed at Merck in the late 1950s, distinguished from later monoamine reuptake inhibitors by broad receptor polypharmacology spanning serotonin and norepinephrine transporters, voltage-gated sodium channels, NMDA receptors, histamine H1, muscarinic acetylcholine, and alpha-1 adrenergic receptors, supporting clinical applications across major depression, neuropathic pain, migraine prophylaxis, fibromyalgia, and irritable bowel syndrome.

    Abstract

    Amitriptyline (3-(10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-N,N-dimethyl-1-propanamine) is a first-generation tricyclic antidepressant (TCA) and the second member of the tricyclic class to reach the market, approved by the United States Food and Drug Administration in 1961 for the treatment of major depressive disorder. Originally developed at Merck Sharp and Dohme as a structural analog of imipramine in which the diamine bridge nitrogen is replaced by an exocyclic propylidene chain, amitriptyline inhibits the serotonin transporter (SERT) and norepinephrine transporter (NET) with low-nanomolar affinity for both targets (Ki approximately 3.1 nM for SERT, 19 nM for NET), producing dual monoamine reuptake inhibition that is mechanistically ancestral to the modern selective serotonin-norepinephrine reuptake inhibitors. Amitriptyline is distinguished from the SSRIs and SNRIs, however, by extensive polypharmacology at secondary targets: the compound acts as a potent antagonist at histamine H1 receptors (Ki approximately 1.1 nM), muscarinic acetylcholine receptors (Ki approximately 14 nM), and alpha-1 adrenergic receptors (Ki approximately 24 nM); as a use-dependent blocker of voltage-gated sodium channels through binding at the local anesthetic receptor site; and as an open-channel blocker of NMDA-type glutamate receptors with an IC50 in the low-micromolar range. This composite receptor profile produces the broad clinical utility of amitriptyline but also the anticholinergic, sedative, and cardiovascular adverse-event burden that has driven displacement by narrower-spectrum agents in the primary antidepressant indication.

    Despite the decline of tricyclic antidepressant prescribing for depression in the SSRI era, amitriptyline remains one of the most widely prescribed medications worldwide. The World Health Organization lists amitriptyline on its Model List of Essential Medicines. The compound is a first-line treatment for neuropathic pain in multiple international guidelines (NICE, AAN, NeuPSIG), supported by decades of randomized controlled trial evidence in painful diabetic neuropathy, postherpetic neuralgia, and mixed neuropathic pain syndromes. The 2022 OPTION-DM trial, the largest head-to-head crossover neuropathic pain trial ever conducted, demonstrated equivalent analgesic efficacy of amitriptyline, duloxetine, and pregabalin monotherapy in diabetic peripheral neuropathic pain, with combination therapy producing superior analgesia. The 2023 ATLANTIS trial, the largest randomized controlled trial of a tricyclic antidepressant in irritable bowel syndrome, demonstrated that low-dose titrated amitriptyline (10 to 30 mg daily) was superior to placebo as second-line treatment for IBS in primary care across multiple symptom endpoints at 6 months. Amitriptyline is recommended for migraine prophylaxis (NNT approximately 3 to 4 for 50 percent headache frequency reduction) and for fibromyalgia analgesia, and it retains clinical use in tension-type headache, insomnia comorbid with chronic pain, nocturnal enuresis, and selected anxiety disorders.

    Pharmacokinetics are dominated by hepatic metabolism through two principal cytochrome P450 pathways: CYP2C19-mediated N-demethylation to the active metabolite nortriptyline (itself a potent and selective NET inhibitor) and CYP2D6-mediated hydroxylation to 10-hydroxymetabolites that are subsequently glucuronidated and renally excreted. Both CYP2C19 and CYP2D6 exhibit clinically significant genetic polymorphism. The Clinical Pharmacogenetics Implementation Consortium (CPIC) has published dosing guidelines for amitriptyline indexed to CYP2D6 and CYP2C19 genotype, recommending dose reduction or alternative agent selection in CYP2D6 poor metabolizers and CYP2C19 ultrarapid metabolizers. Plasma elimination half-life ranges from 10 to 28 hours across the population; oral bioavailability is approximately 45 percent owing to substantial first-pass hepatic metabolism.

    The compound is well tolerated at the low doses (10 to 50 mg) used for pain and functional gastrointestinal indications but produces dose-dependent anticholinergic (dry mouth, constipation, urinary retention, blurred vision), antihistaminic (sedation, weight gain), and cardiovascular (orthostatic hypotension, tachycardia, QT prolongation, QRS widening) adverse events at the higher doses (100 to 300 mg) used for depression. Amitriptyline has a narrow therapeutic index; ingestion of 10 to 20 mg/kg is potentially life-threatening through sodium channel blockade producing cardiac conduction delay, ventricular dysrhythmias, and myocardial depression. This monograph documents the chemistry, synthesis, and structural class of amitriptyline; the multi-target receptor pharmacology; the comprehensive human pharmacokinetic record including CYP2C19 and CYP2D6 pharmacogenomics; the clinical evidence base across depression, neuropathic pain, migraine, fibromyalgia, irritable bowel syndrome, and other indications; sourcing and quality verification considerations; reconstitution and handling; stack-interaction implications; adverse-event signal; and a structured comparative assessment of five analgesic alternatives (duloxetine, pregabalin, gabapentin, nortriptyline, desipramine) against amitriptyline on five competency standards.

    Read the full monograph

    The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

    KDC-MN-216Open in new tab →

    Download PDF →

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

  • Agmatine

    Plain-language summaryIntrigue 55 / 100

    Agmatine is a naturally occurring small molecule made in the body from arginine. It modulates several systems including NMDA receptors, nitric oxide, and imidazoline receptors. Used as a supplement for nerve pain and mood. Not stocked by Kodiac. This monograph is provided for research and educational reference.

    Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

    Endogenous polyamine neuromodulator with multi-target activity at NMDA receptors, imidazoline receptors, alpha-2 adrenoceptors, and nitric oxide synthase

    A decarboxylated arginine metabolite and endogenous neuromodulator distinguished by concurrent NMDA receptor channel blockade, imidazoline receptor agonism, selective inducible nitric oxide synthase inhibition, and alpha-2 adrenoceptor activation, with emerging clinical evidence in neuropathic pain, depression, and neuroprotection.

    Abstract

    Agmatine (4-aminobutylguanidine) is an endogenous cationic amine produced by the decarboxylation of L-arginine via the mitochondrial enzyme arginine decarboxylase. First isolated in 1910 by the Nobel laureate Albrecht Kossel from herring sperm protamine hydrolysates, agmatine was rediscovered in 1994 as an endogenous mammalian neuromodulator synthesized, stored in synaptic vesicles, and released in a calcium-dependent manner from neurons in the hippocampus, hypothalamus, locus coeruleus, and other brain regions. The compound operates through a pharmacologically unusual multi-target profile: it produces voltage-dependent blockade of NMDA receptor-gated cation channels at an intrachannel pore site (IC50 approximately 300 micromolar); it binds with high affinity to imidazoline I1 receptors (Kd approximately 0.7 micromolar) and I2 receptors (Kd approximately 1 micromolar); it activates alpha-2 adrenoceptors (Kd approximately 4 micromolar); and it competitively inhibits inducible nitric oxide synthase (Ki approximately 220 micromolar) with selectivity over the neuronal and endothelial isoforms. This composite mechanism produces neuroprotective, analgesic, antidepressant, and anti-inflammatory activity across a broad range of preclinical models, including excitotoxic and ischemic neuronal injury, traumatic brain injury, neuropathic and inflammatory pain, and behavioral models of depression and anxiety.

    Clinical evidence, though still early-phase and limited in scale, has demonstrated efficacy of oral agmatine sulfate in lumbar disc-associated radiculopathy in a randomized, double-blind, placebo-controlled trial at 2,670 mg per day for 14 days, with statistically significant pain reduction versus placebo [1]. A pilot open-label case series in painful small fiber neuropathy reported approximately 46 percent mean pain reduction over two months at the same dose [2]. A 2026 prospective open-label case series at Massachusetts General Hospital reported preliminary evidence for agmatine sulfate augmentation in treatment-resistant obsessive-compulsive disorder, with 40 percent of patients achieving clinically meaningful improvement on the Yale-Brown Obsessive Compulsive Scale [3]. Preclinical antidepressant-like activity has been demonstrated in the forced swimming test and tail suspension test across multiple laboratories, mediated through NMDA receptor blockade, nitric oxide synthase inhibition, and AMPA receptor and mTOR signaling activation. The compound modulates opioid pharmacology in a biphasic manner: it potentiates acute morphine analgesia while preventing the development of analgesic tolerance and physical dependence, a profile that has attracted substantial research interest in the context of the opioid crisis.

    Safety data are favorable. A long-term safety case report documented 5 years of continuous daily intake at 2.67 g agmatine sulfate with no adverse events, and postmarketing surveillance of 1,015 individuals consuming the same regimen for periods of 3 weeks to 3 years identified no adverse events [4]. Clinical trial adverse events have been limited to mild, transient gastrointestinal symptoms (nausea, diarrhea, abdominal discomfort) at the highest studied doses. The compound is commercially available as a dietary supplement (agmatine sulfate) in multiple jurisdictions. This monograph reviews the chemistry, biosynthesis, and multi-target pharmacology of agmatine; the pharmacokinetic profile including oral bioavailability and CNS distribution; the preclinical and clinical evidence base across neuropathic pain, depression, neuroprotection, and opioid modulation; sourcing and quality considerations; reconstitution and handling; stack interactions; adverse-event signal; and a comparative assessment of five mechanistically related compounds against agmatine on five competency standards.

    Read the full monograph

    The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

    KDC-MN-075Open in new tab →

    Download PDF →

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

  • ABT-737

    Plain-language summaryIntrigue 50 / 100

    ABT-737 is the structural and pharmacological predecessor to navitoclax: same target profile (BCL-2, BCL-XL, BCL-W), same BH3-mimetic logic, same selective killing of senescent cells in animal models, but missing the modifications that made navitoclax orally bioavailable. So ABT-737 is a research-only compound, given by intraperitoneal injection in mouse studies and never developed for clinical use. It remains widely used in cancer biology and senolytic research as a comparator for newer BCL-2 family inhibitors and as a tool to probe BH3-mimetic biology in cell lines and primary cells. Of historical interest as the original molecule that established the senolytic potential of the BCL-2 family. Not stocked by Kodiac. This monograph is provided for research and educational reference.

    Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

    BH3 mimetic inhibitor of anti-apoptotic Bcl-2 family proteins (Bcl-2, Bcl-xL, Bcl-w)

    A potent, cell-permeable BH3-mimetic small molecule developed at Abbott Laboratories by fragment-based drug design, capable of high-affinity binding to the hydrophobic groove of Bcl-2, Bcl-xL, and Bcl-w to displace pro-apoptotic BH3-only proteins and trigger Bak/Bax-dependent mitochondrial apoptosis in Bcl-2-dependent tumor cells and senescent cells.

    Abstract

    ABT-737 is a rationally designed BH3 mimetic small molecule that binds with sub-nanomolar affinity (Ki less than 1 nM) to the BH3-binding groove of the anti-apoptotic proteins Bcl-2, Bcl-xL, and Bcl-w, displacing sequestered pro-apoptotic effectors (Bax, Bak) and BH3-only activators (Bid, Bim) to trigger the intrinsic mitochondrial apoptotic pathway [1]. Developed at Abbott Laboratories (now AbbVie) and reported by Oltersdorf et al. in 2005, ABT-737 was the product of a landmark structure-activity relationships by nuclear magnetic resonance (SAR-by-NMR) fragment-based drug discovery campaign in which two small-molecule fragments identified by NMR chemical shift perturbation screening against Bcl-xL were chemically linked and iteratively optimized by parallel synthesis and X-ray crystallography-guided design to yield a compound approximately three orders of magnitude more potent than any prior Bcl-2 family inhibitor [1, 2]. The compound binds weakly (Ki greater than 460 nM) to the structurally related anti-apoptotic proteins Mcl-1 and Bfl-1/A1, a selectivity gap that defines both the therapeutic window and the principal resistance mechanism observed across tumor models.

    In preclinical studies, ABT-737 demonstrated potent single-agent antitumor activity in xenograft models of small-cell lung cancer (SCLC), follicular lymphoma, and chronic lymphocytic leukemia (CLL), producing complete tumor regressions in SCLC models derived from H146 and H187 cell lines and inducing rapid apoptosis in primary CLL cells at an EC50 of approximately 7 nM [1, 3, 4]. Activity extends to acute myeloid leukemia (AML) blasts and leukemia stem cells, multiple myeloma cell lines with Bcl-2 dependence, and several solid tumor models in combination with conventional chemotherapy or targeted agents [5, 6, 7]. The compound preferentially induces apoptosis in malignant cells while showing reduced activity against normal hematopoietic progenitors at equivalent concentrations, a selectivity attributed to the elevated Bcl-2 dependence of transformed cells relative to their normal counterparts.

    A critical limitation of ABT-737 is its lack of oral bioavailability and poor aqueous solubility, properties that confined it to parenteral administration in preclinical models and precluded direct clinical development [1]. These pharmacokinetic constraints motivated the subsequent design of navitoclax (ABT-263), an orally bioavailable analog with equivalent target selectivity, and ultimately venetoclax (ABT-199), a Bcl-2-selective derivative that eliminated the dose-limiting thrombocytopenia caused by Bcl-xL inhibition in platelets [8, 9]. Venetoclax received FDA approval in 2016 for CLL and subsequently for AML, validating the therapeutic hypothesis that ABT-737 established preclinically.

    Beyond oncology, ABT-737 has been characterized as a senolytic agent capable of selectively clearing senescent cells through disruption of the Bcl-2/Bcl-xL-dependent survival program that senescent cells upregulate as part of the senescence-associated anti-apoptotic phenotype (SAAP) [10]. Administration of ABT-737 during the second half of life in progeroid mouse models abrogated senescence markers and increased median survival, extending the compound’s research relevance to aging biology, fibrosis, and tissue regeneration [10, 11].

    This monograph documents the chemistry, synthesis, and fragment-based discovery of ABT-737; the molecular pharmacology of BH3-groove binding and Bak/Bax activation; pharmacokinetic properties and in vivo dosing; the preclinical evidence base across hematologic malignancies, solid tumors, and senescence; sourcing and quality verification considerations; reconstitution and handling; stack interactions and combination strategies; the adverse-event and safety signal (principally Bcl-xL-mediated thrombocytopenia); and a structured comparative assessment of five BH3 mimetic and Bcl-2 family inhibitors (navitoclax, venetoclax, obatoclax, S63845, and AT-101) against ABT-737 on five competency standards.

    Read the full monograph

    The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

    KDC-MN-299Open in new tab →

    Download PDF →

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

  • Anastrozole

    Plain-language summaryIntrigue 65 / 100

    Anastrozole (Arimidex) is a third-generation aromatase inhibitor approved in 1995, first-line for postmenopausal hormone-receptor-positive breast cancer. It blocks the aromatase enzyme, which converts androgens (including testosterone) into estrogens. At the standard 1 mg daily dose, it lowers plasma estradiol by about 80 percent. In breast cancer this slows or shrinks estrogen-driven tumors. Off-label, low doses are used by anabolic steroid users to control estrogen conversion and prevent gynecomastia. Side effects include joint stiffness and accelerated bone loss (because estrogen is essential for bone in both sexes). The ATAC trial established its superiority over tamoxifen in postmenopausal women. Not stocked by Kodiac. This monograph is provided for research and educational reference.

    Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

    Third-generation nonsteroidal aromatase inhibitor (triazole derivative)

    A potent, selective, reversible nonsteroidal aromatase inhibitor developed at Zeneca Pharmaceuticals for the adjuvant treatment of estrogen receptor-positive breast cancer, distinguished from steroidal inactivators by triazole-mediated competitive binding, oral bioavailability, and a long terminal half-life permitting once-daily dosing.

    Abstract

    Anastrozole (ZD1033, Arimidex) is a third-generation nonsteroidal aromatase inhibitor of the triazole class that selectively and reversibly inhibits the cytochrome P450 19A1 (CYP19A1, aromatase) enzyme complex responsible for the terminal step in estrogen biosynthesis: the conversion of androstenedione to estrone and testosterone to estradiol. At the approved oral dose of 1 mg once daily, anastrozole achieves greater than 96 percent suppression of plasma estradiol in postmenopausal women and approximately 97 percent inhibition of whole-body aromatase activity, without measurable effects on adrenocortical steroidogenesis, aldosterone production, or thyroid function. The compound was developed at Zeneca Pharmaceuticals (now AstraZeneca) through systematic optimization of triazole-bearing aromatase inhibitor scaffolds and received United States Food and Drug Administration approval in 1995 for the treatment of advanced breast cancer in postmenopausal women following tamoxifen therapy, with subsequent label expansions to first-line advanced disease (2000) and adjuvant treatment of early-stage hormone receptor-positive breast cancer (2002).

    The pivotal Arimidex, Tamoxifen, Alone or in Combination (ATAC) trial, enrolling 9,366 postmenopausal women with early-stage invasive breast cancer, established anastrozole as superior to tamoxifen on disease-free survival, time to recurrence, time to distant recurrence, and incidence of contralateral breast cancer at 100-month and 10-year analyses, with a carryover benefit extending beyond the 5-year treatment period. The International Breast Cancer Intervention Study II (IBIS-II) subsequently demonstrated a 49 percent reduction in breast cancer incidence in high-risk postmenopausal women receiving anastrozole 1 mg daily for 5 years compared to placebo, with a persistent preventive effect beyond the active treatment period at 131 months of median follow-up. Anastrozole is now among the most widely prescribed endocrine therapies in oncology, with established roles in adjuvant, neoadjuvant, extended adjuvant, and chemoprevention settings for estrogen receptor-positive breast cancer.

    Pharmacokinetics are characterized by rapid oral absorption (time to peak concentration approximately 2 hours), high oral bioavailability (approximately 85 percent), extensive hepatic metabolism through N-dealkylation, hydroxylation, and glucuronidation (with a principal inactive triazole metabolite), and a long terminal elimination half-life of 40 to 50 hours that supports once-daily dosing and achieves steady-state plasma concentrations within approximately 7 days. Anastrozole is not a potent inhibitor or inducer of cytochrome P450 enzymes at therapeutic concentrations, and clinically significant drug-drug interactions are uncommon. The compound is well tolerated; the principal adverse events are hot flashes, arthralgia, fatigue, and musculoskeletal stiffness, with the most clinically significant long-term safety signal being accelerated bone mineral density loss and increased fracture risk attributable to profound estrogen suppression, managed in clinical practice through concurrent bisphosphonate therapy and bone density monitoring.

    Beyond the oncology indication, anastrozole has been investigated as an off-label research tool for modulating the hypothalamic-pituitary-gonadal axis in males, where aromatase inhibition reduces the conversion of testosterone to estradiol, relieves estrogen-mediated negative feedback on gonadotropin secretion, and increases endogenous testosterone production. This application remains investigational and is not approved by regulatory authorities. This monograph reviews the chemistry, synthesis, and structural class of anastrozole; the molecular pharmacology of aromatase inhibition; the comprehensive pharmacokinetic record; preclinical pharmacology; the clinical evidence base across adjuvant, neoadjuvant, chemoprevention, and investigational indications; sourcing and quality verification; reconstitution and handling; stack interactions and combinations; adverse events and safety signals; and a comparative assessment of five alternative aromatase-modulating agents against anastrozole on five competency standards.

    Read the full monograph

    The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

    KDC-MN-276Open in new tab →

    Download PDF →

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

  • 7-Hydroxymitragynine

    Plain-language summaryIntrigue 60 / 100

    7-Hydroxymitragynine is the more potent mu-opioid agonist alkaloid in kratom and is also a metabolite of mitragynine. It is sold as a concentrated alkaloid product with greater opioid activity than whole kratom. Not stocked by Kodiac. This monograph is provided for research and educational reference.

    Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

    Terpenoid indole alkaloid with mu-opioid receptor partial agonism and G-protein biased signaling

    A potent oxidative metabolite of mitragynine from Mitragyna speciosa (kratom) distinguished by mu-opioid receptor partial agonism with G-protein biased signaling, oral analgesic activity exceeding morphine potency, and an emerging regulatory landscape reflecting both therapeutic promise and abuse liability.

    Abstract

    7-Hydroxymitragynine (7-OH) is a terpenoid indole alkaloid isolated from the leaves of Mitragyna speciosa Korth. (kratom), first characterized by Ponglux, Takayama, and colleagues in 1994 as a minor constituent comprising less than 2 percent of the total alkaloid content of Thai kratom leaf material [1]. The compound is the C7-hydroxylated derivative of mitragynine, the principal alkaloid of kratom, and is generated both as a natural biosynthetic product in the plant and as a hepatic metabolite of mitragynine through cytochrome P450 3A (CYP3A) isoform-mediated oxidation in mammalian systems [2, 3]. 7-Hydroxymitragynine binds the mu-opioid receptor (MOR) with high affinity (Ki approximately 7 to 70 nM depending on the assay system and radioligand employed), approximately 5- to 46-fold greater than mitragynine, and produces antinociception in rodent hot-plate and tail-flick models at potencies approximately 13-fold greater than morphine on a weight basis after subcutaneous administration and with superior oral bioactivity [4, 5]. The compound functions as a partial agonist at the mu-opioid receptor, with G-protein biased signaling that results in minimal recruitment of beta-arrestin-2, a downstream effector linked to opioid-induced respiratory depression, constipation, and tolerance in the beta-arrestin hypothesis of opioid pharmacology [6, 7]. At delta-opioid (DOR) and kappa-opioid (KOR) receptors, 7-hydroxymitragynine acts as a competitive antagonist, a selectivity profile that distinguishes it from classical full opioid agonists such as morphine and fentanyl [8].

    The pharmacokinetic profile of 7-hydroxymitragynine in humans has been characterized in healthy volunteer studies of oral kratom administration. Maximum plasma concentrations are achieved approximately 1.2 to 2.0 hours after ingestion, with an elimination half-life of approximately 2.5 to 5 hours after single dosing that extends to approximately 24 hours with repeated administration [9, 10]. The compound is formed hepatically from mitragynine through CYP3A4-mediated oxidation; co-administration of the CYP3A4 inhibitor itraconazole reduces 7-hydroxymitragynine Cmax by approximately 56 percent and AUC by 43 percent while increasing mitragynine exposure 1.5-fold, confirming the CYP3A4 dependence of the metabolic conversion [10]. Preclinical studies demonstrate that chronic administration of 7-hydroxymitragynine produces opioid-type physical dependence, tolerance, and naloxone-precipitated withdrawal in mice, with cross-tolerance to morphine [11]. Respiratory depression occurs at potencies approximately 3-fold greater than morphine, though the ceiling effect characteristic of partial agonism may limit the magnitude of respiratory suppression relative to full agonists at equianalgesic doses [12].

    The regulatory landscape for 7-hydroxymitragynine is rapidly evolving. In July 2025, the United States Food and Drug Administration recommended that the Drug Enforcement Administration schedule synthetic and concentrated 7-hydroxymitragynine as a Schedule I controlled substance, while indicating that natural kratom leaf products are not the focus of the scheduling recommendation [13]. Several U.S. states, including Florida, Louisiana, Mississippi, and Colorado, have independently scheduled concentrated 7-hydroxymitragynine products [13]. The compound is not approved for any therapeutic indication in any jurisdiction. This monograph reviews the chemistry, biosynthesis, and semisynthesis of 7-hydroxymitragynine; the opioid receptor pharmacology with emphasis on biased signaling; the human and animal pharmacokinetic record; the preclinical analgesic, tolerance, and dependence evidence; the limited clinical and epidemiological data; sourcing and quality verification; reconstitution and handling; stack-interaction considerations; adverse events and safety signals; and a comparative assessment of five kratom-derived or structurally related opioid analgesic candidates against 7-hydroxymitragynine on five competency standards.

    Read the full monograph

    The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

    KDC-MN-156Open in new tab →

    Download PDF →

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

  • ACP-105

    Plain-language summaryIntrigue 38 / 100

    ACP-105 is a tricyclic SARM from Acadia Pharmaceuticals that binds the androgen receptor with high affinity and shows the typical SARM profile of muscle and bone effects with reduced prostate activity in castrated rat models. Acadia briefly explored cognitive applications based on androgen receptor expression in the prefrontal cortex and hippocampus, but development never reached human trials. There are no published pharmacokinetic data in people. It is sold as a research chemical primarily on the strength of its name appearing in old patent literature. The evidence base is thin even by SARM standards. Not stocked by Kodiac. This monograph is provided for research and educational reference.

    Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

    Nonsteroidal selective androgen receptor modulator (SARM) with partial agonist activity and tissue-selective anabolic profile

    A chlorinated aryl nitrile selective androgen receptor modulator discovered at ACADIA Pharmaceuticals through receptor selection and amplification technology screening, distinguished by partial agonist activity at the androgen receptor, tissue-selective anabolic effects on muscle and bone with minimal prostatic stimulation, and preclinical neuroprotective activity in irradiation and Alzheimer’s disease models.

    Abstract

    ACP-105 (2-chloro-4-[(3-endo)-3-hydroxy-3-methyl-8-azabicyclo[3.2.1]oct-8-yl]-3-methylbenzonitrile) is a nonsteroidal selective androgen receptor modulator (SARM) identified in 2006 at ACADIA Pharmaceuticals AB through high-throughput screening employing receptor selection and amplification technology (R-SAT) and published in the Journal of Medicinal Chemistry in 2009 as the lead compound of a novel aryl nitrile series [1]. The compound binds the androgen receptor with high affinity (pEC50 of 9.0 at the wild-type human androgen receptor and 9.4 at the clinically relevant T877A mutant) and functions as a partial agonist relative to the full agonist activity of testosterone and dihydrotestosterone [1]. In vitro, ACP-105 is reported to be as potent as testosterone in androgen receptor functional assays without measurable interaction at other steroid hormone receptors, including estrogen, progesterone, glucocorticoid, and mineralocorticoid receptors. In vivo, in a two-week chronic study in castrated male rats, the compound improved anabolic parameters (levator ani muscle mass) at approximately 66 percent of the efficacy of testosterone while producing only approximately 21 percent of the androgenic stimulation of the prostate, yielding a favorable anabolic-to-androgenic dissociation ratio of approximately 3:1 [1, 2].

    The compound crosses the blood-brain barrier with a reported brain-to-plasma ratio of 2.7, a property that has motivated investigation in central nervous system models [3, 4]. In a 2011 study by Dayger et al., subcutaneous administration of ACP-105 at 1 mg/kg/day to female C57BL/6J mice protected against 137-cesium irradiation-induced impairment of sensorimotor function on the rotarod and enhanced cued fear conditioning in both sham-irradiated and irradiated animals, with immunohistochemical evidence of region-specific modulation of microtubule-associated protein 2 (MAP-2) in the sensorimotor cortex [3]. In a 2013 study by George et al. in gonadectomized male triple-transgenic Alzheimer’s disease mice (3xTg-AD), ACP-105 at 10 mg/kg administered intraperitoneally four days per week reduced anxiety-like behavior when given alone and, when co-administered with the selective estrogen receptor beta agonist AC-186, improved long-term spatial memory on the Morris water maze, increased the amyloid-beta degrading enzymes neprilysin and insulin-degrading enzyme, and reduced brain amyloid-beta 40 and amyloid-beta 42 levels after seven months of treatment [4].

    Predicted and in silico absorption, distribution, metabolism, and excretion (ADME) profiling indicates high gastrointestinal absorption (94 to 100 percent), moderate lipophilicity (LogP 3.0 to 3.5), strong plasma protein binding (77 to 99 percent), and primary hepatic metabolism through CYP3A4 with secondary contributions from CYP2C19, CYP1A2, CYP2C9, and CYP2D6 [5]. In vivo metabolite identification studies in rats, horses, and humans have collectively characterized 21 or more phase I and phase II metabolites, predominantly monohydroxylated and bishydroxylated species formed on the azabicyclic ring system, along with glucuronide conjugates [6, 7, 8]. Predicted plasma half-life is approximately 1.18 hours, though this value derives from computational models and has not been confirmed in formal human pharmacokinetic studies [5].

    ACP-105 has never entered human clinical trials. No Phase 1, Phase 2, or Phase 3 studies are registered or reported. The compound was nominated as a development candidate by ACADIA Pharmaceuticals in February 2006 for potential treatment of muscle wasting and osteoporosis, and preclinical data were presented at the Experimental Biology 2008 meeting, but development was subsequently discontinued. The compound is classified as a prohibited substance under World Anti-Doping Agency (WADA) regulations since 2008, and adverse analytical findings for ACP-105 have appeared in routine sports doping control samples [6, 9]. Research-grade ACP-105 is available from multiple chemical suppliers at greater than 98 percent purity. This monograph reviews the chemistry, structure-activity relationships, and characterization of ACP-105; the androgen receptor partial agonist mechanism and tissue selectivity; the available absorption, distribution, metabolism, and excretion data; the preclinical pharmacology in musculoskeletal and central nervous system models; the absence of clinical evidence; sourcing and quality verification; reconstitution and handling; stack interaction considerations; adverse event and safety signals; and a comparative assessment of five alternative SARM compounds against ACP-105 on five competency standards.

    Read the full monograph

    The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

    KDC-MN-270Open in new tab →

    Download PDF →

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

  • Allopregnanolone

    Plain-language summaryIntrigue 80 / 100

    Allopregnanolone is a neurosteroid metabolite of progesterone that powerfully potentiates GABA-A receptors. Recombinant allopregnanolone (brexanolone) is FDA-approved for postpartum depression. Not stocked by Kodiac. This monograph is provided for research and educational reference.

    Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

    Endogenous neurosteroid and positive allosteric modulator of GABA-A receptors with dual synaptic and extrasynaptic activity

    An endogenous pregnane neurosteroid and the most potent known positive allosteric modulator of GABA-A receptors, reduced to clinical practice as brexanolone (Zulresso) for postpartum depression and serving as the pharmacophore template for the orally bioavailable derivative zuranolone.

    Abstract

    Allopregnanolone (3alpha-hydroxy-5alpha-pregnan-20-one; 3alpha,5alpha-tetrahydroprogesterone; brexanolone) is an endogenous C21 pregnane neurosteroid biosynthesized from progesterone by sequential 5alpha-reductase and 3alpha-hydroxysteroid oxidoreductase activity in the central nervous system, adrenal cortex, ovary, and placenta. First isolated from adrenal tissue in 1938 and identified as a potent positive allosteric modulator of GABA-A receptors by Majewska and colleagues in 1986, allopregnanolone occupies a singular position in neuropsychopharmacology as the most potent endogenous modulator of inhibitory GABAergic neurotransmission. At low nanomolar concentrations, the compound allosterically enhances GABA-gated chloride currents at both synaptic (alpha-beta-gamma-containing) and extrasynaptic (alpha-beta-delta-containing) GABA-A receptor subtypes; at higher micromolar concentrations, it directly gates the chloride channel in the absence of GABA. The extrasynaptic receptor preference distinguishes allopregnanolone from benzodiazepines and underlies its characteristic anxiolytic, anticonvulsant, sedative-hypnotic, and antidepressant pharmacology.

    The translational trajectory of allopregnanolone spans more than eight decades. Selye reported the anesthetic properties of pregnane steroids in 1941. Baulieu and colleagues proposed the “neurosteroid” concept in 1981 after demonstrating de novo brain synthesis independent of peripheral endocrine sources. Majewska et al. (1986) established the GABA-A receptor mechanism. Paul and Purdy (1992) coined “neuroactive steroid” to encompass synthetic analogs acting through non-genomic receptor modulation. The modern clinical program began at Sage Therapeutics, which developed an intravenous formulation of synthetic allopregnanolone (designated SAGE-547, later brexanolone) for postpartum depression (PPD). Two Phase 3 randomized, double-blind, placebo-controlled trials (Meltzer-Brody et al. 2018) demonstrated rapid, clinically meaningful, and sustained reductions in Hamilton Depression Rating Scale (HAM-D) scores following a 60-hour continuous intravenous infusion. The United States Food and Drug Administration approved brexanolone (Zulresso) in March 2019 as the first therapy specifically indicated for PPD, subject to a Risk Evaluation and Mitigation Strategy (REMS) program requiring inpatient administration with continuous pulse oximetry monitoring owing to the risks of excessive sedation and loss of consciousness.

    A parallel clinical program led by Roberta Diaz Brinton at the University of Arizona has investigated allopregnanolone as a regenerative therapeutic for Alzheimer’s disease, grounded in preclinical demonstrations that the compound promotes hippocampal neural stem cell proliferation, neurogenesis, oligogenesis, and restoration of cognitive function in transgenic Alzheimer’s models and wild-type aged mice. A Phase 1b/2a multiple ascending dose trial (NCT02221622) in early Alzheimer’s disease reported safety, tolerability, and exploratory neuroimaging signals including preservation of hippocampal volume and functional connectivity changes after 12 weeks of intermittent intravenous dosing. Additional clinical investigations have evaluated allopregnanolone in fragile X-associated tremor/ataxia syndrome (FXTAS), status epilepticus, traumatic brain injury, and essential tremor.

    The principal pharmacokinetic limitation of endogenous allopregnanolone is negligible oral bioavailability (less than 5 percent), necessitating intravenous, subcutaneous, or intramuscular administration. This limitation drove development of orally bioavailable synthetic analogs, most notably zuranolone (SAGE-217), a deuterated allopregnanolone analog approved by the FDA in August 2023 for PPD, and ganaxolone (3beta-methyl allopregnanolone), approved for seizures associated with CDKL5 deficiency disorder in March 2022. Allopregnanolone is metabolized by extra-hepatic non-CYP pathways, principally keto-reduction, glucuronidation, and sulfation, with an elimination half-life of approximately 9 hours after intravenous infusion, a volume of distribution of approximately 3 L/kg, and greater than 99 percent plasma protein binding. The compound is a controlled substance (Schedule IV in the United States). This monograph reviews the chemistry, biosynthesis, receptor pharmacology, pharmacokinetics, preclinical and clinical evidence base across all studied indications, sourcing and quality verification, reconstitution and handling, stack-interaction considerations, adverse-event profile, and a structured comparative assessment of five neurosteroid GABA-A receptor modulators against allopregnanolone on five competency standards.

    Read the full monograph

    The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

    KDC-MN-159Open in new tab →

    Download PDF →

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

  • Amantadine

    Plain-language summaryIntrigue 60 / 100

    Amantadine started life in 1968 as an oral antiviral for influenza A and was later discovered to help Parkinson disease patients, an entirely accidental finding that led to its current main role. It works through several mechanisms at once: weak NMDA glutamate receptor blockade (similar to memantine), dopamine release, and dopamine reuptake inhibition. Today it is most useful for the involuntary movements (dyskinesias) that develop after years of L-DOPA therapy, and for cognitive recovery after traumatic brain injury where it has the strongest evidence base of any drug. The flu indication has largely been abandoned because of widespread viral resistance. Not stocked by Kodiac. This monograph is provided for research and educational reference.

    Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

    Adamantane-derived multi-target neurotherapeutic agent with weak NMDA receptor antagonism, sigma-1 receptor agonism, and indirect dopaminergic activity

    A tricyclic adamantane amine originally developed as an influenza A antiviral, subsequently repositioned for Parkinson’s disease and levodopa-induced dyskinesia, distinguished by a polypharmacological profile spanning NMDA receptor antagonism, sigma-1 receptor agonism, dopaminergic facilitation, and nicotinic acetylcholine receptor modulation.

    Abstract

    Amantadine (1-adamantanamine) is a small-molecule adamantane derivative that has undergone three distinct phases of clinical development since its original synthesis in the 1960s: as the first synthetic antiviral agent active against influenza A virus through blockade of the M2 ion channel protein; as an antiparkinsonian agent discovered serendipitously in 1968 and subsequently approved for the treatment of drug-induced extrapyramidal reactions and as adjunctive therapy in Parkinson’s disease; and, most recently, as a delayed-release and extended-release formulation (Gocovri) approved by the United States Food and Drug Administration in 2017 for the treatment of levodopa-induced dyskinesia in Parkinson’s disease. The compound occupies a distinctive position in clinical neuropharmacology by virtue of a polypharmacological profile that engages multiple molecular targets at therapeutically relevant concentrations. At the N-methyl-D-aspartate (NMDA) receptor, amantadine acts as a weak, non-competitive, open-channel blocker that accelerates channel closure during channel block, producing glutamatergic modulation at concentrations achievable with standard oral dosing. At the sigma-1 receptor, amantadine acts as an agonist with a Ki of approximately 7.44 micromolar, a mechanism that has been linked to the modulation of dopaminergic neurotransmission including enhancement of tyrosine hydroxylase activity, facilitation of striatal dopamine release, and inhibition of dopamine reuptake. The compound also functions as a negative allosteric modulator of alpha-4-beta-2 and alpha-7 nicotinic acetylcholine receptors, with IC50 values in the low-micromolar range, and exerts additional effects on potassium channels, aromatic amino acid decarboxylase, and glial-cell-derived neurotrophic factor expression.

    The clinical evidence base for amantadine now spans six decades and includes approved indications in Parkinson’s disease (both as monotherapy for mild symptoms and as adjunctive therapy for levodopa-induced dyskinesia), drug-induced extrapyramidal reactions, and influenza A prophylaxis and treatment (now largely obsolete owing to widespread viral resistance). Off-label applications with meaningful clinical support include acceleration of functional recovery in traumatic brain injury with disorders of consciousness, as demonstrated in the landmark Giacino et al. (2012) randomized placebo-controlled trial published in the New England Journal of Medicine; management of fatigue in multiple sclerosis; and reduction of chorea in Huntington disease. Pharmacokinetics are characterized by high oral bioavailability (86 to 90 percent), minimal hepatic metabolism with predominantly renal excretion of unchanged drug, a plasma elimination half-life of approximately 12 hours in subjects with normal renal function (extending to 7 to 10 days in severe renal impairment), and the absence of significant cytochrome P450 involvement. The adverse-event profile includes central nervous system effects (insomnia, dizziness, hallucinations, confusion), peripheral edema, the distinctive dermatological finding of livedo reticularis, and, at supratherapeutic doses or in overdose, QT prolongation and cardiac arrhythmias. This monograph reviews the chemistry, synthesis, and structural class of amantadine; the multi-target molecular pharmacology in mechanistic detail; comprehensive pharmacokinetics; the clinical evidence base across all approved and investigational indications; sourcing, reconstitution, and handling considerations for laboratory work; stack-interaction implications; adverse-event signal; and a comparative assessment of five alternative agents (memantine, rimantadine, budipine, safinamide, and istradefylline) against amantadine on five competency standards.

    Read the full monograph

    The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

    KDC-MN-319Open in new tab →

    Download PDF →

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.